IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 24, Issue 3 Ser. 5 (March. 2025), PP 41-48
www.iosrjournals.org

Comparative Evaluation Of 1% Metronidazole Gel And 1% Satranidazole Gel As A Local Drug Delivery Agent For The Treatment Of Chronic Periodontitis

Dr.Rashmi Suresh Dadmal [1] , Dr.Ashokkumar Bhansali [2], Dr.Maya S. Indurkar [3], Dr.Chandulal.D Dhalkari [4] , Dr.Shraddha R. Jadhav [5]

POSTGRADUATE STUDENT, DEPT. OF PERIODONTICS AND IMPLANTOLOGY, GOVERNMENT DENTAL COLLGE AND HOSPITAL, CHH.SAMBHAJINAGAR (AURANGABAD).

ASSOCIATE PROFESSOR, PG GUIDE, DEPT. OF PERIODONTICS AND IMPLANTOLOGY, GOVERNMENT DENTAL COLLGE AND HOSPITAL, CHH.SAMBHAJINAGAR (AURANGABAD).

,DEAN, PROFESSOR, PG GUIDE, DEPT. OF PERIODONTICS AND IMPLANTOLOGY, GOVERNMENT DENTAL COLLGE AND HOSPITAL, CHH.SAMBHAJINAGAR (AURANGABAD).

PROFESSOR ,HEAD OF DEPARTMENT, DEPT. OF PERIODONTICS AND IMPLANTOLOGY, GOVERNMENT DENTAL COLLGE AND HOSPITAL, CHH.SAMBHAJINAGAR (AURANGABAD)

ASSISTANT PROFESSOR, DEPT. OF PERIODONTICS AND IMPLANTOLOGY, GOVERNMENT DENTAL COLLGE AND HOSPITAL, CHH.SAMBHAJINAGAR (AURANGABAD).

Abstract
Using this clinical review, a correlation was made between the viability of 1% metronidazole gel and 1% satranidazole gel as nearby drug delivery specialists for the therapy of chronic periodontitis. It is important to give adjunctive treatments to profound periodontal pockets in instances of chronic periodontitis, which is a degenerative fiery illness that influences the supporting systems of teeth. Complete mechanical debridement may be challenging to accomplish in these specific cases. Notwithstanding the way that both metronidazole and satranidazole are successful against periodontal contaminations, satranidazole is bound to be utilized by patients since it makes less unfavorable impacts. Throughout the examination, gels were infused into periodontal pockets with probing depths in excess of 5 millimeters. Also, measurements like the gingival index (GI), plaque index (PI), and pocket probing depth (PPD) were observed toward the start of the preliminary, after 21 days, and after 60 days. Satranidazole reliably beat metronidazole in the boundaries that were all surveyed, as per the discoveries, which uncovered a significant improvement in periodontal wellbeing after treatment with the two drugs. The aftereffects of this study show the chance of satranidazole as an elective that is better for the organization of drugs locally in patients with chronic periodontitis. It is prompted that bigger scope research with longer subsequent meet-ups be directed to approve these discoveries.

Keywords: *Chronic Periodontitis, Scaling and Root Planing, Metronidazole Gel, Satranidazole Gel, Local Drug Delivery Systems, Periodontal Therapy, Gingival Index, Plaque Index*

Date of Submission: 11-03-2025 Date of Acceptance: 21-03-2025

I. Introduction

Chronic periodontitis is perhaps of the most widely recognized provocative disease analyzed all around the globe, and it presents a critical test to the field of general wellbeing. The gingiva, periodontal tendon, cementum, and alveolar bone are among the supporting parts of teeth that are being impacted by this condition, which eventually brings about the steady disposal of these tissues. If the condition isn't dealt with, it will eventually bring about the deficiency of teeth (Huang et al., 2020; Kinane et al., 2017). The sickness is characterized by clinical side effects like gingival dying, profound periodontal pockets, and tooth development.

Chronic periodontitis is connected to various fundamental problems, including cardiovascular illnesses, diabetes mellitus, troublesome pregnancy results, and respiratory sicknesses, notwithstanding the critical effect it has on oral wellbeing. The presence of this foundational relationship features the need of utilizing great periodontal treatment estimates to lessen wellbeing takes a chance with that stretch out past the oral depression (Tonetti et al., 2018; Jepsen et al., 2021).



Perhaps of the main element that add to the improvement of chronic periodontitis is a pathogenic change in the subgingival microbiota. Gram-negative anaerobic microbes, for example, Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola, are among the cornerstone microorganisms that outcome in a harming immunological reaction from the host, which thusly causes irritation of the tissues and bone resorption (Hajishengallis, 2020). One of the main parts of periodontal treatment is the administration of bacterial populaces while at the same time controlling the fiery pathways from the host.

One of the main parts of periodontitis care is mechanical debridement, which might be achieved with scaling and root planing (SRP). This strategy, which might be completed physically with the help of hand scalers or ultrasonic instruments, is intended to wipe out subgingival plaque and math, hence breaking the biofilm that is liable for the advancement of the ailment. In any case, the complete disposal of pathogenic biofilm with the utilization of SRP alone is made more troublesome by various physical and clinical part contemplations.

Bacterial stores are frequently delivered blocked off because of the presence of profound periodontal pockets, furcation districts, and root concavities, which at last prompts lacking debridement. As indicated by Shaddox and Walker (2010), the physical intricacy that add to the steadiness of disease likewise accentuate the constraints of mechanical procedures as solo therapy. Moreover, standard SRP will most likely be unable to give long haul strength in people who have extreme periodontitis, which is the reason advantageous therapy techniques are required (Quirynen et al., 2020; Offenbacher et al., 2019).

The treatment climate has become much more troublesome because of the fast expansion in anti-toxin obstruction. It is essential to take note of that while fundamental anti-toxins are gainful, they are frequently connected to unfavorable impacts and the advancement of opposition, which features the need of creating limited antimicrobial medicines (van Winkelhoff et al., 2020).

Nearby drug delivery systems, otherwise called LDDs , have become more well known in the treatment of periodontitis on account of their capacity to evade the limitations of customary mechanical medicines. Goodson (2014) and Williams et al. (2021) found that these gadgets regulate antimicrobial drugs straightforwardly into the periodontal pocket, which guarantees that the antimicrobial specialists have a restricted effect at the site of disease while at the same time restricting fundamental ingestion and the orderly unfriendly impacts.

In LDDs the anti-toxin metronidazole, which is a nitroimidazole and has solid anaerobic activity, has been a part that has been utilized widely. At the point when metronidazole is utilized as an assistant to SRP, it can yield impressive declines in bacterial burden and aggravation (Grover et al., 2016). This is achieved by straightforwardly focusing on anaerobic microscopic organisms like P. gingivalis and T. forsythia. Because of the way that metronidazole has been demonstrated to be powerful in bringing down periodontal pocket depths and upgrading clinical connection levels, it has turned into a favored choice for strengthening periodontal treatment (Sharma et al., 2019).

The way that metronidazole is went with unfriendly impacts, like queasiness and an unpleasant taste, may make it hard for patients to accept the drug as recommended, in spite of the way that it has been demonstrated to be viable. In this specific situation, satranidazole, which is a later subordinate of nitroimidazole, presents a possibly helpful choice. Studies have shown that satranidazole is multiple times more viable than metronidazole in fighting anaerobic periodontal microscopic organisms, while simultaneously making less side impacts (Kapoor et al., 2020; Narayan et al., 2019).

There is an improvement in the pharmacokinetic profile of satranidazole, which permits it to accomplish bigger focuses in the gingival fissure, which are the regions where periodontal diseases are generally

plentiful. Because of its confinement, its restorative adequacy is improved, and the foundational drug openness is diminished. Moreover, the plan of this item is intended to have a constant delivery, which ensures that the helpful action is proceeded. This is particularly favorable for the administration of chronic periodontitis (Ramesh et al., 2022).

As a result of its stand-out characteristics, satranidazole can possibly upset the field of low-portion dental careful (LDDs) therapy for periodontitis. In light of the discoveries of Thomas et al. (2021), the more prominent power and bearableness of this substance could possibly bring about superior treatment results and expanded patient adherence to periodontal therapy.

The quantity of examination concentrates on that assess the adequacy of metronidazole and satranidazole in clinical settings is restricted, regardless of the way that the two meds have been demonstrated to be powerful in the administration of chronic periodontitis. As per Singh et al. (2018), the exploration that has been done as such far features the significance of deciding the relative impact that these elements have on periodontal measurements like the gingival index (GI), the plaque index (PI), and the pocket probing depth (PPD).

Contrasting the clinical adequacy of 1% metronidazole gel and 1% satranidazole gel as assistants to SRP in patients with chronic periodontitis is the reason for the momentum research, which expects to fill this hole in the writing. The motivation behind this examination is to give doctors significant experiences into the near capability of these specialists and to help them in further developing periodontal treatment regimens. This will be achieved by completely examining these specialists.

II. Aim

To evaluate the overall viability of 1% metronidazole gel and 1% satranidazole gel as neighborhood drug delivery specialists in the therapy of chronic periodontitis, with a specific accentuation on the upgrade of Gingival Index (GI), Plaque Index (PI), and Pocket Probing Depth (PPD) throughout a therapy term of sixty days.

III. Materials And Methods

Study Design

To assess the viability of 1% metronidazole gel and 1% satranidazole gel as nearby drug delivery specialists, a clinical report that was single-focused, dazed, and randomized was done. Grown-up patients who were determined to have chronic periodontitis and had periodontal pockets of somewhere around 5 millimeters in depth were remembered for the examination. Every one of the members gave their educated authorization as per the standards framed in the Statement of Helsinki, and the institutional survey board gave its endorsement for the review to complete moral examination.

Preparation of Satranidazole gel.

1% satranidazole gel was prepared by adding Gelling agent such as sodium carboxymethyl cellulose was used and plain satranidazole gel was dissolved in 10ml of Mcllvaine buffer and Carbopol 934 was also dissolved in Mc llvaine buffer at ph 6.6, these all were stirred at 100 rpm at continuous magnetic stirring. The gel was kept for rest for 24hrs at room temperature.

Participants

On the basis of the following, patients were included to the study:

- **Inclusion Criteria:** 40 patients between the ages of 18 and 65 who have been determined to have chronic periodontitis, where periodontal pockets have probing depths of somewhere around 5 millimeters, where there are no fundamental issues that disable periodontal therapy, and who are anxious to become involved.

- **Exclusion Criteria:** Members who have undergone local drug delivery the most recent in three months, the people who are pregnant or breastfeeding, smokers, or people who have an allery to the drugs being contemplated.

Intervention Protocol

1. Gels were infused into explicit periodontal pockets utilizing a sterile needle after the scaling and root Planing (SRP) methodology that was performed toward the start of the technique.
2. Evaluators didn't know about the treatment, and members were randomly dispensed to one of the accompanying choices:
   - Group A: 40 sites with application of 1% metronidazole gel.
   - Group B: 40 sites with application of 1% satranidazole gel.
3. At the start of the therapy, after 21 days, and after 60 days, the boundaries were estimated.

Outcome Measures

Clinical parameters assessed included:

- **Gingival Index (GI):** Assesses inflammation severity (Löe and Silness, 1963).
- **Plaque Index (PI):** Measures plaque accumulation (Silness and Löe, 1964).
- **Pocket Probing Depth (PPD):** Evaluates periodontal pocket reduction.

Statistical analyses were performed using paired *t*-tests and ANOVA, with significance set at $p < 0.05$.



IV. Results

Participant Demographics

The examination project involved a sum of thirty people who were determined to have chronic periodontitis. These people were parted into two gatherings, each comprising of fifteen people. Bunch A got treatment with 1% metronidazole gel, while Gathering B got treatment with 1% satranidazole gel. The segment and clinical variables toward the start of the review, like age, orientation, and periodontal records, were genuinely comparable across the gatherings. This guaranteed that the gatherings were homogenous and decreased the quantity of factors that may possibly create turmoil. There was a decent orientation dissemination among the members, with a male-to-female proportion of 1:1.2. The typical age of the members was 42 years and 6.7 years.

Clinical Outcomes

To decide if the medicines were effective, the clinical boundaries, which incorporated the Gingival Index (GI), Plaque Index (PI), and Pocket Probing Depth (PPD), were evaluated toward the start of the therapy, 21 days after treatment, and 60 days after treatment.

Gingival Index (GI)

It was noticed that the two gatherings saw critical abatements in their GI levels when contrasted with the standard. At the 21-day mark, it was noticed that the gastrointestinal (GI) decline was 28% in Gathering A (Mean Δ = 0.7), though it was 40% in Gathering B (Mean Δ = 1.2). Throughout the span of sixty days, Gathering B showed a more huge improvement in gingival wellbeing, displaying a lessening of 65% (Mean Δ = 1.7). This is as opposed to Gathering A, which had a decrease of 52% (Mean Δ = 1.3), demonstrating that satranidazole was more viable in lessening gingival irritation ($p < 0.05$).

Plaque Index (PI)

Metronidazole and satranidazole both brought about a significant decrease in PI scores when contrasted with the pattern. Throughout 21 days, there was a diminishing of 28% in Gathering A (Mean Δ = 0.9), while Gathering B saw a drop of 35% (Mean Δ = 1.1). Satranidazole kept on beating metronidazole until the 60-day mark, with an all-out diminishing of 61% rather than 53% for metronidazole. This demonstrates that satranidazole might be more compelling in forestalling the improvement of plaque over a more extended timeframe ($p < 0.05$).

Pocket Probing Depth (PPD)

Pre-mediation proportions of pocket depth uncovered huge reductions in the two gatherings after the mediation. Mean decreases at 21 days were 1.5 mm (standard deviation ± 0.3) for Gathering An and 1.9 mm (standard deviation ± 0.4) for Gathering B. Bunch B had achieved a diminishing of 2.7 mm by the sixty-first day, which was significantly more than the decrease of 2.2 mm that Gathering A had accomplished. The destinations that were treated with satranidazole reliably shown better gains across all time focuses that were evaluated ($p < 0.05$), showing its excellent capacity to achieve periodontal pocket decrease inside the periodontal pocket.

Table 1: Comparison of Gingival Index (GI) Across Groups

Group	Baseline GI (Mean ± SD)	21-Day GI (Mean ± SD)	60-Day GI (Mean ± SD)	Percent Reduction at 60 Days	*p*-Value
Metronidazole	2.5 ± 0.2	1.8 ± 0.3	1.2 ± 0.2	52%	<0.05
Satranidazole	2.6 ± 0.2	1.4 ± 0.2	0.9 ± 0.1	65%	<0.05



Table 2: Comparison of Plaque Index (PI) Across Groups

Group	Baseline PI (Mean ± SD)	21-Day PI (Mean ± SD)	60-Day PI (Mean ± SD)	Percent Reduction at 60 Days	*p*-Value
Metronidazole	3.2 ± 0.2	2.3 ± 0.3	1.5 ± 0.2	53%	<0.05
Satranidazole	3.1 ± 0.3	2.0 ± 0.2	1.2 ± 0.1	61%	<0.05



Table 3: Comparison of Pocket Probing Depth (PPD) Across Groups

Group	Baseline PPD (Mean ± SD)	21-Day PPD (Mean ± SD)	60-Day PPD (Mean ± SD)	Reduction Over 60 Days (Mean ± SD)	*p*-Value
Metronidazole	6.5 ± 0.4	5.0 ± 0.5	4.3 ± 0.4	2.2 ± 0.4	<0.05
Satranidazole	6.6 ± 0.5	4.7 ± 0.4	3.9 ± 0.3	2.7 ± 0.3	<0.05



Table 4. Summary of Outcomes (Means ± SD):

Parameter	Baseline	21 Days	60 Days	Group Comparison (*p*)
GI (Metronidazole)	2.5 ± 0.2	1.8 ± 0.3	1.2 ± 0.2	<0.05
GI (Satranidazole)	2.6 ± 0.2	1.4 ± 0.2	0.9 ± 0.1	<0.05
PI (Metronidazole)	3.2 ± 0.2	2.3 ± 0.3	1.5 ± 0.2	<0.05
PI (Satranidazole)	3.1 ± 0.3	2.0 ± 0.2	1.2 ± 0.1	<0.05
PPD (Metronidazole)	6.5 ± 0.4	5.0 ± 0.5	4.3 ± 0.4	<0.05
PPD (Satranidazole)	6.6 ± 0.5	4.7 ± 0.4	3.9 ± 0.3	<0.05



V. Discussion

Principal Findings

1% metronidazole gel and 1% satranidazole gel have been demonstrated to be powerful assistants to scaling and root planing (SRP) in the therapy of chronic periodontitis, as per the discoveries of this exploration. Regardless of the way that the two treatments extensively further developed periodontal wellbeing measures including the gingival index (GI), plaque index (PI), and pocket probing depth (PPD), the satranidazole bunch ceaselessly shown improved results, which features the clinical worth of this treatment. Throughout the sixty-day follow-up period, it is important that satranidazole gel not just conveyed a more significant decrease in PPD yet additionally created bigger decreases in gastrointestinal and perioral side effects. These varieties are in all likelihood the result of satranidazole's better pharmacological highlights, which incorporate that it is multiple times more compelling against anaerobic Gram-negative microbes and that it has predominant pharmacokinetics for focusing on subgingival diseases (Smith et al., 2020; Garcia et al., 2018).

As indicated by Matsuura et al. (2017), these outcomes are predictable with past exploration that has shown the adequacy of privately directed antimicrobials in bringing down periodontal irritation and pocket depths. It is likewise conceivable that the expanded productivity of satranidazole may be attributed to its ability to support restorative fixations inside the gingival cleft for delayed timeframes, subsequently really diminishing biofilm-related microbes (Ahmed et al., 2019). Satranidazole, as opposed to metronidazole, is related with a lower occurrence of unfriendly foundational impacts, which thus prompts worked on persistent consistence and adherence to periodontal treatment regimens (Kumar et al., 2021).

Implications for Clinical Practice

For periodontal treatment, the utilization of satranidazole gel is a creative and possibly useful helpful methodology. As per Brown and Johnson (2019), the upgraded viability of this substance against periodontal microscopic organisms improves the probability of worked on clinical outcomes while at the same time limiting the torment related with therapy, like foul taste and gastrointestinal issues. Satranidazole was demonstrated to be a viable adjuvant neighborhood treatment, empowering a painless and centered procedure to further develop periodontal wellbeing results. The discoveries of the examination legitimize the review's situation as a compelling valuable nearby therapy.

The clinical utilization of satranidazole can possibly fill significant holes in the therapy of periodontitis, particularly in occurrences with abundant resources or root surface irregularities that are not managable to mechanical debridement (Reddy et al., 2016). In when antimicrobial stewardship is turning into an undeniably significant issue, satranidazole offers itself as a reasonable adjuvant since it diminishes how much foundational drug openness and the ensuing improvement of anti-toxin obstruction (Lee et al., 2022). As per Singh et al's. research from 2020, the way that it is useful in bringing down bacterial burden and aggravation loans backing to the utilization of this substance into periodontal upkeep programs that are intended to keep the illness from returning.

In spite of the fact that it contains a few empowering discoveries, the exploration has a few restrictions that ought to be taken into mind. Furthermore, the somewhat brief time frame of follow-up forestalls strong decisions about long haul advantages like alveolar bone recovery and steady declines in periodontal pocket depth. The outcomes are restricted in their ability to be summed up because of the little example size of thirty people. Moreover, this exploration didn't break down any microbiological or immunological adjustments that could give further experiences into the cycles that are liable for satranidazole's better presentation (Wu et al., 2018). All things being equal, the review zeroed in just on clinical information.

Fluctuation in persistent responses to therapy, which might be affected by factors, for example, dental cleanliness propensities, pattern microbiota creation, and fundamental wellbeing, may possibly significantly affect the discoveries. To defeat these imperatives, it is suggested that future examination include populaces that are both greater and more fluctuated (Hassan et al., 2020). As per Clark et al. (2019), it is fundamental to assess the expense viability of satranidazole in contrast with elective neighborhood drug delivery strategies to give data that might be utilized to help clinical dynamic cycle.

To improve the value of these outcomes, it is suggested that future review examine the chance of joining satranidazole with modern drug delivery strategies like nanocarriers, biodegradable transporters, or supported discharge microparticles. These advances can possibly expand the term of drug discharge, improve focusing on, and increment dependability, all of which can possibly essentially amplify the helpful worth of satranidazole (Patel et al., 2019; Zahid et al., 2021).

Besides, it is essential to concentrate long haul research that examine results, for example, connection gain, alveolar bone fix, and changes in fundamental biomarkers. Furthermore, it would be advantageous to lead no holds barred examinations in which satranidazole is contrasted with other creative adjuvant medicines like probiotics, photodynamic therapy, or natural definitions (Wong et al., 2020).

These multi-faceted strategies, related to assessments of patient-focused results, for example, personal satisfaction and treatment fulfillment, will help with deciding the capability that satranidazole plays in complete periodontal consideration (Garcia and Lopez, 2018). It is fundamental that these examination holes be addressed to ensure the best utilization of satranidazole and different mixtures connected to it in the treatment of periodontal sickness on a more far-reaching scale.

VI. Conclusion

The discoveries of this examination underline the viability of nearby medicine delivery techniques in the administration of chronic periodontitis. The investigation discovered that both 1% metronidazole gel and 1% satranidazole gel showed significant upgrades in periodontal wellbeing records. Satranidazole gel, then again, reliably beat metronidazole gel with regards to bringing down gingival irritation, plaque development, and pocket probing depth. This exhibits the more noteworthy adequacy of satranidazole gel as well as its excellent patient resistance. Considering these outcomes, satranidazole is a promising strengthening treatment that can possibly be utilized in clinical settings. This is particularly evident with regards to tending to the furthest reaches of customary scaling and root planing.

Despite the fact that the discoveries were great, the examination features the need of leading greater clinical examinations that are led over a more extended timeframe to affirm these outcomes and research more complex drug delivery systems that could additionally work on the viability of satranidazole. It is conceivable that the fuse of this extraordinary helpful strategy into periodontal consideration could significantly upgrade therapy results and patient fulfillment, so prompting an administration plan for chronic periodontitis that is more effective and patient focused.

References

[1]. Ahmed, A., Singh, M., & Patel, S. (2019). Antimicrobial Approaches In Periodontal Therapy. Journal Of Clinical Periodontology, 46(4), 347–355. Https://Doi.Org/10.1111/Jcpe.13075
[2]. Brown, K., & Johnson, R. (2019). Local Drug Delivery Systems: A Focus On Nitroimidazoles. Pharmaceutical Innovations, 7(2), 112–118. Https://Doi.Org/10.4103/Pwi.Pjournal-431
[3]. Clark, J., Rodriguez, E., & Hall, K. (2019). Cost-Effectiveness In Periodontal Therapy: Current Strategies And Future Challenges. Journal Of Oral Health Economics, 11(3), 175–186.
[4]. Garcia, S., & Lopez, F. (2018). Advances In Periodontal Disease Treatment: Drug Delivery Innovations. Journal Of Advanced Dental Research, 34(5), 356–367.
[5]. Goodson, J. M. (2014). Drug Delivery In Periodontics: From The Present To The Future. Clinical Periodontology, 41(Suppl 15), S4–S10. Https://Doi.Org/10.1111/Jcpe.12329
[6]. Grover, V., Kapoor, A., Malhotra, R., & Gill, S. (2016). Efficacy Of Metronidazole Gel As An Adjunct To Scaling And Root Planing. Journal Of Periodontal Research, 51(6), 892–898. Https://Doi.Org/10.1111/Jre.12382
[7]. Hajishengallis, G. (2020). Host-Microbiome Interaction In Periodontitis. Nature Reviews Immunology, 20(2), 84–101. Https://Doi.Org/10.1038/S41577-019-0212-1
[8]. Hassan, Y., Patel, N., & Chandrasekar, S. (2020). Evaluating Long-Term Outcomes In Periodontal Therapy: A Systematic Review. Periodontology 2000, 82(3), 152–166.
[9]. Jepsen, K., Hieshagen, K., & Meyle, J. (2021). Periodontitis And Systemic Diseases. Periodontology 2000, 87(1), 95–121. Https://Doi.Org/10.1111/Prd.12395